Compare BioNTech SE - ADR (BNTX) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs General Dynamics Corporation — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while General Dynamics Corporation trades at $391.11 (market cap $107.13B). The key difference: General Dynamics Corporation is far larger — about 4.6× BioNTech SE - ADR's market cap, and General Dynamics Corporation pays a 1.61% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | GD | |
|---|---|---|
Market Cap | $23.31B | $107.13B |
Sector | Health | Industrials |
52-Week High | $119.34 | $395.97 |
52-Week Low | $83.89 | $312.53 |
Enterprise Value | $6.60B | $112.28B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
General Dynamics (GD) trades at $392.05, up 1.33% today, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $4.24 versus $3.96 expected, with revenue growth across all segments. A $76.6 billion Navy contract awarded in July 2026 bolsters its backlog to $136.5 billion, providing visibility for future growth.
The stock offers upside to the $427.40 consensus price target, driven by defense spending tailwinds and operational execution. Risks include valuation at a 23.91 P/E and potential contract execution delays. Analyst sentiment is positive with 57% buy ratings, but overbought RSI levels near-term may limit gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
